Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcellx Inc (ACLX)

Arcellx Inc (ACLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,696,544
  • Shares Outstanding, K 58,480
  • Annual Sales, $ 22,290 K
  • Annual Income, $ -228,930 K
  • EBIT $ -253 M
  • EBITDA $ -255 M
  • 60-Month Beta 0.22
  • Price/Sales 300.17
  • Price/Cash Flow N/A
  • Price/Book 16.44

Options Overview Details

View History
  • Implied Volatility 8.24% (-8.94%)
  • Historical Volatility 165.87%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 85.06% on 05/14/25
  • IV Low 8.24% on 03/17/26
  • Expected Move (DTE 3) 0.60 (0.53%)
  • Put/Call Vol Ratio 9.62
  • Today's Volume 308
  • Volume Avg (30-Day) 957
  • Put/Call OI Ratio 4.11
  • Today's Open Interest 17,386
  • Open Int (30-Day) 14,100
  • Expected Range 113.92 to 115.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.13
  • Number of Estimates 3
  • High Estimate -1.05
  • Low Estimate -1.20
  • Prior Year -1.13
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.15 +81.36%
on 02/20/26
114.80 -0.24%
on 03/06/26
+44.32 (+63.13%)
since 02/17/26
3-Month
60.35 +89.74%
on 01/05/26
114.80 -0.24%
on 03/06/26
+49.80 (+76.95%)
since 12/17/25
52-Week
47.86 +139.28%
on 05/07/25
114.80 -0.24%
on 03/06/26
+41.78 (+57.44%)
since 03/17/25

Most Recent Stories

More News
Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 114.52 (+0.01%)
GLDD : 16.95 (+0.12%)
MASI : 175.97 (+0.32%)
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Arcellx , Inc....

ACLX : 114.52 (+0.01%)
GILD : 144.40 (-0.56%)
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 114.52 (+0.01%)
AVO : 12.16 (+2.88%)
CVGW : 24.36 (+1.12%)
DBRG : 15.38 (-0.13%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--ACLX, VRE, EHAB, and CECO

NEW YORK , March 4, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

ACLX : 114.52 (+0.01%)
EHAB : 13.62 (+0.07%)
VRE : 18.86 (-0.11%)
CECE : 11.65 (+2.19%)
Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 114.52 (+0.01%)
VRE : 18.86 (-0.11%)
LSF : 2.42 (-6.20%)
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

ACLX : 114.52 (+0.01%)
XLV : 149.64 (-0.91%)
MRK : 115.87 (+0.38%)
GILD : 144.40 (-0.56%)
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Arcellx , Inc....

ACLX : 114.52 (+0.01%)
GILD : 144.40 (-0.56%)
Are ACLX, VRE, UHG, EHAB Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 114.52 (+0.01%)
EHAB : 13.62 (+0.07%)
UHG : 1.1600 (unch)
VRE : 18.86 (-0.11%)
Stocks Finish Sharply Lower on Trade Uncertainty and AI-Disruption Fears

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -1.04%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.21%. March E-mini...

MSTR : 150.28 (+1.87%)
APP : 459.09 (+1.28%)
GLXY : 23.50 (+1.73%)
VRE : 18.86 (-0.11%)
DASH : 169.81 (+1.21%)
COIN : 210.23 (+3.40%)
CLW : 13.33 (+1.29%)
VFC : 16.59 (+3.49%)
MA : 506.58 (-0.38%)
^BTCUSD : 74,485.12 (-0.11%)
SPY : 670.79 (+0.26%)
DOCU : 47.54 (+1.54%)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Arcellx, Inc. (NASDAQ: ACLX)

NEW YORK , Feb. 23, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions...

ACLX : 114.52 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Arcellx Inc. is a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc. is based in GAITHERSBURG, Md.

See More

Key Turning Points

3rd Resistance Point 114.85
2nd Resistance Point 114.73
1st Resistance Point 114.63
Last Price 114.52
1st Support Level 114.41
2nd Support Level 114.29
3rd Support Level 114.19

See More

52-Week High 114.80
Last Price 114.52
Fibonacci 61.8% 89.23
Fibonacci 50% 81.33
Fibonacci 38.2% 73.43
52-Week Low 47.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar